22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting also being accepted.
The ICER today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of eculizumab (Soliris, Alexion Pharmaceuticals) and efgartigimod (argenx, Halozyme Therapeutics, and Zai Lab) for the treatment of myasthenia gravis.